Clinical Trial Update: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone plus Olaparib in patients with metastatic castrat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Olaparib (Olaparib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Northwestern University | Conditions: Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair | Phase 2 | Status: ACTIVE_NOT_RECRUITING